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Abstract
Background: Although there was growing evidence in the potential use of Bisphosphonates (BPs) in cancer therapy, their
strong osseous affinities that contrast their poor soft tissue uptake limited their use. Here, we developed a new strategy to
overcome BPs hydrophilicity by masking the phosphonic acid through organic protecting groups and introducing
hydrophobic functions in the side chain.
Methodology/Principal Findings: We synthesized non-nitrogen BPs (non N-BPs) containing bromobenzyl group (BP7033Br)
in their side chain that were symmetrically esterified with hydrophobic 4-methoxphenyl (BP7033BrALK) and assessed their
effects on breast cancer estrogen-responsive cells (T47D, MCF-7) as well as on non responsive ones (SKBR3, MDA-MB-231
and its highly metastatic derived D3H2LN subclone). BP7033Br ALK was more efficient in inhibiting tumor cell proliferation,
migration and survival when compared to BP7033Br. Although both compounds inhibited tumor growth without side
effects, only BP7033Br ALK abrogated tumor angiogenesis and D3H2LN cells-induced metastases formation.
Conclusion/Significance: Taken together these data suggest the potential therapeutic use of this new class of esterified
Bisphosphonates (BPs) in the treatment of tumor progression and metastasis without toxic adverse effects.
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Introduction
Bisphosphonates (BPs) had long been used in metabolic bone
disease as osteoporosis, tumor-associated hypercalcaemia and
metastases-induced osteolysis due to their ability to inhibit bone
resorption. BPs were able to bind divalent cations like Ca
2+ or zinc
constituting the basis of their bone-targeting property and their
inhibition of the proteolytic activity of matrix metalloproteinases
(MMP), respectively. The nature of their side chains gave rise to a
variety of possible structures and stereochemistry determining
their different potencies [1–4]. Non-nitrogen containing BPs (non
N-BPs) acted by forming non hydrolysable ATP-analogues and
were less effective than nitrogen-containing BPs (N-BPs) in
inhibiting bone metastasis [5]. However, Zoledronate treatment
of patients were reported to induce toxic side effect characterised
by osteonecrosis of the jaw while non N-BP did not produce this
effect [6,7]. N-BPs, such as zoledronate, acted on the mevalonate
pathway inhibiting the farnesyl diphosphate synthase (FPP)
thereby depleting the cells of the farnesyl (FPP) or geranylgeranyl
(GGPP) diphosphate isoprenoids [8]. Isoprenoids were required
for translocation and anchorage of small G proteins like Rho or
Ras to the plasma membrane assuring their ultimate involvement
in signal transduction during several important normal and tumor
cellular pathways.
However, in vivo efficacy of all BPs on extra-osseous sites or
primary tumors was still debated. Only a small number of studies
demonstrated their in vivo antiproliferative activity on tumors or
metastasis present in soft tissues [9]. The reasons were the poor
oral bioavaibility (0.3–7% in humans) due to chelation of metal
ions by phosphonic acid group inside the digestive lumen, poor
membrane permeability due to poor BP lipophilicity as well as
strong uptake by bone tissue [10]. Previously, our laboratory
developed a new strategy to overcome BP hydrophilicity by
masking the phosphonic acid with organic protecting groups and
introducing hydrophobic functions in the side chain [11]. We
previously demonstrated that an esterified BP with methyl group
displayed antitumor growth and antiangiogenic activities on A431
tumors being more effective in vivo than in vitro [12]. In order to
further increase the lipophilicity of BPs (and their entering into the
cells), we synthesized new aromatic 1-hydroxymethylene-1,1-
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their side chains. Interestingly, we showed that these compounds
exhibited potent antiproliferative activities in vitro on human
epidermoid A431 cells [13]. In parallel, recently crystallographic
and computational investigation revealed that the presence of
phenyl ring in the side chain permitted non N-BPs to interact with
farnesyl enzyme [14]. Thus, we synthesized a class of BPs that
contained bromobenzyl in their side chains (BP7033Br, Fig. 1).
For the first time, we symmetrically esterified one of each
phosphonic acids with aromatic groups (BP7033Br ALK, Fig. 1).
In this study we tested the effects of BP7033Br and BP7033Br
ALK on MDA-MB-231 xenograft growth and metastasis. We
found that the addition of hydrophobic bromobenzyl groups on
non N-BPs side chain rendered them efficient in inhibiting
estrogen responsive as well as non-responsive breast cancer cells
like MDA-MB-231 and metastatic subpopulation (D3H2LN) cell
growth as well as migration and invasion in vitro. Further, we
demonstrated that BP7033Br and BP7033Br ALK differently
reduced the proteolytic activity of MMP-9 and MMP-2. These
two non-N BPs inhibited MDA-MB-231 xenografts associated
with tumor angiogenesis reduction. Importantly, we demonstrated
that only esterification of m-bromobenzyl bisphosphonate revealed
to induce antimetastatic effect in nude mice.
Results
BP7033Br ALK was more potent than BP7033Br in
inhibiting breast cancer cell viability
We investigated the effect of BP7033Br and its esterified
analogue BP7033Br ALK on the proliferation of several breast
cancer cell lines with different estrogen-receptor statuses as T47D
(Fig. 2A), MCF-7 (B), SKBR3 (C), MDA-MB-231(D) and its
D3H2LN metastatic subclone (E). The special features of
D3H2LN subclone are that these cells exhibited more important
tumor growth than MDA-MB-231 and that when injected in the
left heart ventricle, they induced faster metastasis and more
multiple tissues sites [15]. After 72 h, BP7033Br differently
inhibited the several cell lines. The maximal T47D cell viability
inhibition induced by BP7033Br was about 38% and the IC50 was
not reached even at the maximal concentration (1 mM). MCF-7
and SKBR3 cells were inhibited by 50% with 500 mMo f
BP7033Br and this concentration was the more effective for
SKBR3 cells. Viability of both MDA-MB-231 and D3H2LN was
inhibited by BP7033Br in a dose-dependent manner with the same
efficacy (IC50=500 mM, Fig 2B). For these cells, the maximal
effect (80%) was achieved at 1 mM of BP7033Br. Considering
BP7033Br ALK, we showed that this esterified BP was more
effective than BP7033Br on T47D, MCF-7 and SKBR3 cells with
maximal effect achieved at 250 mM. BP7033Br ALK also
inhibited the MDA-MB-231 and D3H2LN cell lines in a dose-
dependent manner with the same efficacy (IC50=170 mM, Fig. 2D
and E). In addition, BP7033Br ALK was at least 4-fold more
efficient than non esterified BP7033Br since maximal inhibition of
cell viability (90%) was reached at 250 mM. Breast cancer cell
viability inhibitions induced by both BPs were also time-dependent
and started after 24 h (data not shown).
BP7033Br and BP7033Br ALK inhibited MDA-MB-231
breast cancer cell viability through different cell cycle
arrests
In order to understand the effect of the BPs on breast cancer cell
viability, we evaluated their effect on cell cycle progression (Fig. 3).
MDA-MB-231 and D3H2LN cells (Fig. 3A and 3B, respectively)
were treated with effective doses of BP7033Br and BP7033Br ALK
for 72 h (500 mM and 200 mM, respectively). BP7033Br blocked
10% of MDA-MB-231 cells into the G0/G1 phase (P=0.0002)
and diminished the cell number in the S phase (P=0.017, Fig. 3C).
In contrast, BP7033Br ALK increased the number of MDA-MB-
231 cells into the S phase (P=0.005) accompanied by a reduction
of the proportion of cells in G0/G1 phase (P,0.001). Concerning
the D3H2LN cells, BP7033Br increased about 20% the number of
cells (P=0.048, Fig. 3D) in the G0/G1 phase, as observed for
MDA-MB-231 cells, and completely inhibited the proportion of
cells in the G2/M phase. Also, BP7033Br ALK increased the
number of D3H2LN cells into the S phase to about 15%
(P=0.006, Fig. 3D).
BP7033Br and BP7033Br ALK induced MDA-MB-231
breast cancer cell death
The Ann-V-positive/PI-negative population corresponds to
cells in an early apoptotic phase and the Ann-V-positive/PI-
Figure 1. Chemical structure of BP7033Br and BP7033Br ALK. The first step (1) was an Arbusov reaction between an activated carboxylic
function and a very reactive species, the bis(trimethylsilyl) phosphite and the second one (2) was hydrolysis.
doi:10.1371/journal.pone.0004685.g001
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the apoptotic effect of efficient doses of both BPs on breast cancer
cell lines. Both BP7033Br (500 mM) and BP7033Br ALK
(200 mM) induced apoptosis of the MDA-MB-231 cells inducing
the same amount of cells in both early and late apoptosis (Fig. 4A).
Total percentage of MDA-MB-231 cells in apoptosis (late plus
early) induced by BP7033Br and BP7033BR ALK is about 37 and
25% as compared to control, respectively (Fig. 4B). The
percentage of apoptotic cells was not significantly different
between the two BPs treatments(P=0.069) although concentration
used for BP7033Br ALK was lower (200 mM) Concerning
D3H2LN cells, the effect of the two BPs was slightly less effective
(20%) as compared to the MDA-MB-231 parental cells (Fig. 4C
and 4D).
BP7033Br and BP7033Br ALK inhibited MDA-MB-231 cells
migration, invasion and MMP-9 and MMP-2 proteolytic
activation
We next explored the effect of BPs on the migration of the two
MDA-MB-231 cell lines (Fig. 5A). MDA-MB-231 cells as well as
D3H2LN subpopulation ones, migrated through the lower
chamber side when 10% FCS-DMEM was used as chemo
attractant. BP7033Br (125 mM) inhibited about 55% the migra-
tion of MDA-MB-231 cells but was less efficient on the D3H2LN
cell migration (32%, P,0.001). The same concentration of
BP7033Br ALK induced stronger motility inhibition of both cell
lines (62 and 50%, respectively). Since invasion is also important in
the metastasis process, we investigated the inhibition induced by
BPs on the MDA-MB-231 cell invasion (Fig. 5B). In the presence
of 10% FCS-DMEM, MDA-MB-231 cell lines invaded the inserts
coated with matrigel. In contrast to the results obtained with
MDA-MB-231 cell migration, we observed a better inhibition of
D3H2LN invasion by BP7033Br as compared to BP7033Br ALK
(84% versus 40%, P,0.001). Concerning the MDA-MB-231 cells,
BP7033Br ALK inhibited cell invasion about 65% whereas
BP7033Br reduced it about 45%.
To further study the BPs effects on invasion, we evaluated the
effect of BPs on MMP activity in the D3H2LN cells (Fig. 5).
D3H2LN cells showed activation of MMP-9 and MMP-2 (lane 1,
Fig. 5C and 5D). BP7033Br strongly inhibited the activation of
MMP-9 (Fig. 5C, lane 2, P=0.0037). In contrast, BP7033Br ALK
only reduced about 45% the MMP-9 activity (Fig. 5C, lane 3,
P=0.0065). In addition, BP7033Br inhibited about 40%
(P=0.001) MMP-2 activity whereas BP7033Br ALK reduced
MMP-2 activation about 25% (P=0.01, Fig. 5D, Lane 2 and 3,
respectively).
Both BP7033Br and BP7033Br ALK inhibited the D3H2LN
tumor growth and angiogenesis in nude mice
All 7 mice developed tumors within one week after D3H2LN
inoculation and the BPs treatments were initiated at the end of the
first week (Fig. 6A). Both BP7033Br and BP7033BR ALK used at
11 mg/kg (286 mg/mouse) twice a week significantly inhibited
D3H2LN growth after 21 days as compared to control (P=0.034
and P=0.038, respectively). D3H2LN tumor growth was inhibited
by about 80% with both BPs. All mice treated with the two BPs
were alive at the end of the treatment and did not present
significant loss of body weight (Figure 6B). In addition, no
macroscopic differences were observed between treated and
control mice liver and kidney after autopsy (data not shown).
Figure 2. BP7033Br and BP7033Br ALK inhibited viability of different breast cancer cells. T47D (A), MCF-7 (B), SKBR3 (C), MDA-MB-231 (D)
or D3H2LN cells (E) (1610
5) were treated with BP7033Br and BP7033Br ALK at increasing concentrations for 72 h. Then, the cells were washed and
incubated with 0.1 mL of MTT (2 mg/mL) for 4 h. Optical density was measured at 570 nm using a Labsystems Multiskan MS microplate reader. Data
represents the mean value (6SD) of three independent experiments.
doi:10.1371/journal.pone.0004685.g002
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to determine the relative density of micro-vessels in D3H2LN
tumors xenografted in nude mice (Fig. 6C–E). BP7033Br ALK
treated tumors exhibited large areas of necrosis (Fig. 6E).
BP7033Br ALK treatment strongly reduced the micro-vessel
density (80%) in viable field of tumors as compared to control and
BP7033Br treatments (Fig. 6F, P=0.01 and P=0.047, respective-
ly).
Only BP7033Br ALK inhibited D3H2LN metastasis
Since D3H2LN was described to develop bone and soft tissues
metastasis after intracardiac injection in nude mice [15], we
further studied the effect of both BPs on this D3H2LN metastasis
model (Fig. 7). Animals (n=7) with successful intracardiac
injection at day 0 (Fig. 7A) were treated with each BPs at
11 mg/kg twice a week during 4 weeks. The control group
received sterile PBS. Injections started the first week when
micrometastasis appeared. Within 2 weeks after intracardiac
injection, all animals exhibited metastasis at multiple sites in the
head, thorax, abdomen, legs or spine (Fig. 7A). Ex vivo imaging of
the different tissues after the final imaging in vivo, showed bone
lesions (legs) as well as lung, lymph nodes, ovary, bladder and liver
ones (Fig 7B). Treatment with BP7033Br ALK at 11 mg/kg twice
a week, induced inhibition about 80% of luminescence signalling
and 50% reduction of the mean metastatic sites number per
animal (P=0.01 and 0.08, respectively, Fig. 7C). In contrast,
BP7033 did not show any significant reduction in metastasis
bioluminescence signals or number sites (Fig. 7D).
Discussion
BPs represented an emerging class of drugs for cancer therapy.
In this work, we demonstrated the efficacy of a new class of non-N-
BPs which exhibited higher antiproliferative activities on breast
cancer cells compared to previously described non-N-BPs such as
clodronate [16]. Both types of m-bromobenzyl BPs inhibited the
viability of several breast cancer cell lines with different estrogen-
receptor statuses. We showed that the esterified BP was the more
effective on estrogen-responsive cells since the maximal inhibition
was reached at 250 mM in contrast to non esterified BP that did
not induce maximal inhibition even at 1 mM. In addition, at
250 mM, BP7033Br ALK is effective on cells independently from
Figure 3. BP7033Br and BP7033Br ALK inhibited MDA-MB-231 breast cancer cell cycle progression. Distribution of MDA-MB-231 (A) and
D3H2LN (B) cells treated with BPs in different cell cycle phases was determined as described in ‘‘Materials and Methods’’. Histograms show the
percentage of MDA-MB-231 (C) and D3H2LN (D) cell repartition. Each column represents a mean (6SD) of three independent experiments.
*P control versus BP7033BrALK and ** P control versus BP7033Br,0.05.
doi:10.1371/journal.pone.0004685.g003
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BPs inhibited MDA-MB-231 breast cancer cell migration (A) and invasion (B). Cells (2.5610
5) with 125 mM of BPs were added to each 8 mm-insert in
the upper chamber of boyden chamber. After 24 h, cells invading the chamber were fixed, stained and counted as described in ‘‘Materials and
Methods’’. BPs inhibited MMP-9 and MMP-2 activities (C and D, respectively). Lyophilized conditioned media were normalized to the number of cells
and subjected to 10% SDS-polyacrylamide gels containing 1 mg/mL gelatine. Lane 1, 2 and 3 represent the control, BP7033Br and BP7033Br ALK
conditioned medium of treated cells, respectively. Each column represents a mean (6SD) of three independent experiments. *Pversus MDA-MB-231 control
,0.05, ** Pversus D3H2LN control,0.05.
doi:10.1371/journal.pone.0004685.g005
Figure 4. BP7033Br and BP7033Br ALK induced MDA-MB-231 breast cancer cell apoptosis. Preconfluent MDA-MB-231 (A) and D3H2LN
(C) cells were treated with 500 mM BP7033Br or 200 mM BP7033Br ALK for 72 h in a serum-containing medium. Percentages of MDA-MB-231 (B) and
D3H2LN (D) were evaluated as described in ‘‘Materials and Methods’’. Each column represents a mean (6SD) of three independent experiments.
doi:10.1371/journal.pone.0004685.g004
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viability of estrogen non-responsive cells and particularly that of
MDA-MB-231 and D3H2LN cells, the last cell line being the
more aggressive ones. It was worth to note that we demonstrated
for the first time a dramatic improvement of antiproliferative effect
of non-N-BPs on breast cancer cells since clodronate at the same
concentration range (200 mM) and the same time-treatment (72 h)
did not reduce MDA-MB-231 cell viability [17–19]. In addition,
clodronate demonstrated mitogenic effects via MCF7 estrogenic
receptor [16] and we never observed this effect with our BPs.
Based on our results, it appears also that BP7033Br ALK
antiproliferative effect is estrogen-receptor-independent. The
occurrence of this new effect of non-N-BPs could result from the
addition of aromatic functions in the side chain. Heterocycle in the
side chain was implicated in the induction of cell apoptosis by
preventing the prenylation of signalling proteins such as Ras or
Rho [20]. We previously demonstrated the inhibition of Ras
processing using non bromo-containing BP7033 [21]. Also, the
addition of phenyl function in the side chain of BPs rendered the
catalytic pocket of geranyl and/or farnesyl synthase enzymes of the
mevalonate pathway more accessible [14,22]. BP7033Br ALK
reduced MDA-MB-231 and D3H2LN cell viabilities about 90%
with a concentration 4-fold inferior to that of BP7033Br. These
data were in agreement with our previous results on epidermoid
A431 cell proliferation that showed a beneficial effect of
esterification of the phosphonic groups [12,13]. Our hypothesis
was that such esterified compounds rendered BPs more hydro-
phobic increasing their cell uptake and could therefore act like
prodrugs releasing active BP into the cells. In accordance,
characterisation of the hydrophilicity demonstrated a shift toward
lipophilicity of the BP7033Br ALK compound (Log P values of
20.75 versus 2031, respectively). Alternatively, one could also
hypothesize that esterified BPs had their own mechanisms since
they blocked the cells into the S phase while non esterified BPs
inhibited the G0/G1 cell phase transition. On the other hand,
both type of BPs (esterified or not) induced cell death apoptosis of
both MDA-MB-231 and D3H2LN cells. These results are
interesting since D3H2LN had a metastatic potential greater than
MDA-MB-231 and consequently could be more resistant to
apoptosis as it was described for metastatic cells [23,24]. Both BPs
induced strong D3H2LN metastatic cell apoptosis but the
concentration of the esterified analogue used was 2-fold lower.
Also, the two BPs inhibited migration of MDA-MB-231 cell lines
with a more important effect obtained with BP7033Br ALK. In
contrast, BP7033Br ALK was less effective in inhibiting D3H2LN
cell lines invasion concomitant with a less important effect on
MMP-9 and MMP-2 activities. BP7033Br strongly inhibited
MMP-9 and MMP-2, the major form of metalloproteinases
present in extracellular matrix. Since MMPs are zinc-dependent
endopeptidases, we speculated that the reduction of BP7033Br
ALK effect could be due to a reduction of available phosphonic
acid groups able to chelate zinc and consequently inhibit MMPs.
Figure 6. BP7033Br and BP7033Br ALK inhibited D3H2LN tumor growth and esterified analogue completely inhibited
angiogenesis. (A) D3H2LN cells were inoculated in nude mice as described in ‘‘Materials and Methods’’. After 1 week, mice were treated with
BPs (11 mg/kg), twice a week, for 21 days. Each column represents the mean of tumor volume (mm
3)( 6SD, n=7). Body weight (BW) ratio was
determined for each group (B). Endothelial cells in tumor sections were stained in controls (C), BP7033Br (D) and BP7033Br ALK (E) Microvessels were
indicated by arrows and necrosis area by double asterisks (magnification6100). Quantification of micro-vessel density (F). Each column represents a
mean (6SD) of three independent experiments. *PBP7033Br and BP7033Br ALKversus control,0.05.
doi:10.1371/journal.pone.0004685.g006
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showed that MMPs inhibition activity by BPs was related to zinc
chelation [2]. However, we hypothesised that release of BP7033Br
ALK with free phosphonic group could be more important in in
vivo system because of the presence of phosphodiesterases in serum.
Also, we found that these BPs had no influence on MMPs
expression (data not shown).
Interesting results were the BPs antitumor effects observed on
D3H2LN xenografts growth and metastasis. D3H2LN cells were
obtained from a MDA-MB-231 subclone isolated from a lymph
node metastases and induced an increased xenograft tumor
growth as compared to parental cells when injected in vivo [15].
Both BP7033Br and BP7033Br ALK inhibited about 80% the
D3H2LN tumor growth after intratumoral injection of about
286 mg BPs per mouse twice a week during 21 days. We
established that this new class of BPs was the more potent among
the current non N-BPs since clodronate, even used at 1600 mg
twice daily during several weeks (as compared to BP7033 ALK
corresponding human dose of 770 mg twice a week during only 2
weeks) failed to reduce primary tumor growth [25]. Also, we found
that our BPs were 10-fold more potent than the non halogenated
phenyl analogues [26]. In addition, BP7033Br ALK better
inhibited D3H2LN vessel density than BP7033Br. This point is
also supported by the large necrosis area not detected in BP7033Br
treated tumors. In addition, we can not exclude that these large
necrosis areas could also be due to a greater amount of esterified
BP penetrating into tumor to induce cell death. As compared to N-
BPs, it was noteworthy that risedronate or ibandronate failed to
inhibit MDA-MB-231 tumor growth in nude mice [27,28].
Furthermore, no pre-clinical works demonstrated an antiprolifer-
ative effect of zoledronate on primary breast tumor growth in nude
mice. The only study demonstrating an inhibition effect of
zoledronate on primary tumor growth used mesothelioma tumors
which involved calcification that could uptake the drug [29]. In
addition, the efficacy of zoledronate on bone metastasis seems to
be supported by its affinity for osseous tissues rather than its direct
antiproliferative effect on tumor cells [25]. Also, zoledronate was a
compound rapidly eliminated from plasma, resulting in renal
excretion, rapid bone or calcified tissues uptake and accumulation
partly due to its phosphonic functions. Here, we showed that the
symmetrical esterification of the phosphonic groups may improved
BPs soft tissue bioavaibility limiting osseous or calcified tissue
Figure 7. Only BP7033Br ALK inhibited D3H2LN metastasis. D3H2LN cells were injected into the left ventricle of nude mice (n=7). Day 0
showed the successful intracardiac cells injection. Within 2 weeks, when metastasis were initiated, mice were treated with BP7033Br ALK or BP7033Br
(A). At the indicated days, the bioluminescence images were acquired for control (c, left panel) and BPs treated mice (BP7033BrALK and BP7033Br
middle and right panel, respectively). Ex vivo data confirm soft tissue metastasis from D3H2LN cells injection (B). Quantification of the mean
metastatic sites and the photons/s after BP7033Br ALK treatment (C). Quantification the photons/s after BP7033Br treatment (D). Each column
represents a mean (6SD) of three independent experiments. *Pversus control,0.05.
doi:10.1371/journal.pone.0004685.g007
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BP which presented aliphatic ester group, we suggested that their
half-life will be close to that found for this drug (156 h with
micromolar plasma concentration, [30]). Thus, esterified
BP7033Br ALK abrogated angiogenesis, both soft tissue and bone
metastasis whereas BP7033Br did not. Noteworthy, in BP7033Br
treated mice, luminescence signalling of leg osseous metastasis was
not significantly reduced because 2/7 mice did not respond to the
treatment in contrast to BP7033Br ALK treatment that induced
significant reduction (data not shown). Indeed, the esterified
functions seem to be important for the BPs distribution within the
systemic system and less for local injection (subcutaneous tumors)
since the two N-BPs studied both inhibited D3H2LN xenograft
growth. To note, was the toxic adverse effects of N-BPs inducing
osteonecrosis of treated patients [7] and no apparent side effect
reported with non N-BPs in the present study.
In conclusion, esterified m-bromobenzyl non N-BPs constituted
a new class of drugs with potent direct antitumor, antiangiogenic
and antimetastatic efficacy on breast tumors.
Materials and Methods
Bisphosphonates synthesis and hydrophilicity
characterisation
The bisphosphonate molecule evaluated in this study corre-
sponds to [2-(3-Bromo-phenyl)-1-hydroxy-1-phosphono-ethyl]-
phosphonic acid (MW: 400 g/L, Fig. 1). This compound
(BP7033Br) was synthesised as previously described [31,32]. The
novel esterified analogue, {2-(3-Bromo-phenyl)-1-hydroxy-1-[hy-
droxy-(4-methoxy-phenoxy)-phosphoryl]-ethyl}-phosphonic acid
mono-(4-methoxy-phenyl) ester named BP7033Br ALK (MW:
572 g/L, Fig. 1), was synthesised following the same methodology
in two steps. Briefly, a very reactive species, the bis(trimethylsi-
lyl)(p-methoxyphe ´nyl) phosphite, was reacted following an Arbusov
(1) reaction with an activated carboxylic function and then the
intermediate was hydrolysed (2). Log P values were determined
using a shake-flask method as described previously [33]. Aqueous
sodium chloride (0.9% w/v) and n-octanol phase were saturated
for a week. Bisphosphonates were dissolved at a concentration of
0.02 M in the aqueous phase (2.5 mL). An equal volume of
saturated n-octanol was added and the solution was mixed. The
content of aqueous phases was determined by UV spectroscopy
respectively at 268 and 278 nm (BP7033 Br and BP7033Br ALK).
The logarithm of the ratio of BPs concentrations in the organic
and aqueous phases was calculated to determine following log P
values: log P(BP7033Br)=20.75 ; log P(BP7033BrALK)=20.31. In
addition, 0at physiological pH both compounds BP7033 Br and
BP7033Br ALK were readily soluble at 2 mM concentration in
both distilled water and aqueous sodium chloride solution (0.9%
w/v). BP7033Br ALK becomes insoluble in water at concentration
higher than 20 mM and below 10 mM in aqueous sodium
chloride solution. BP7033 Br was still soluble at 50 mM in both
solutions.
Cell lines
The human breast adenocarcinoma MDA-MB-231, T47D,
MCF-7 cell lines were obtained from the American Type Culture
Collection (Manassas, VA, USA). SKBR3 were kindly obtained
from Dr Cavailles (U824, CRLC, Montpellier, France). Cells were
maintained in Dulbecco’s minimal essential medium supplement-
ed with 10% fetal bovine serum (FBS), 1% sodium pyruvate and
antibiotics (1% penicillin sodium and 1% streptomycin) at 37uCi n
a humidified atmosphere containing 5% carbon dioxide.
D3H2LN cell line isolated from MDA-MB-231 lymph node
metastasis was obtained from Caliper Life Sciences (Alameda, CA,
USA). D3H2LN cell line was a subclone selected from a MDA-
MB-231 stable clone expressing firely luciferase. MDA-MB-231
cells expressing luciferase were injected into the mammary fad pad
of nude mice and after 12 weeks of growth in vivo, they were
harvested and re-propagated in vitro. This subclone was injected
once more into the mammary fad pad of nude mice to yield a
second cell line D3H2LN, harvested from a lymph node metastasis
[15]. D2H2LN cells were cultured in Minimum Essential Medium
with Earl’s Balanced Salts Solution MEM/EBSS medium
supplemented with 10% fetal bovine serum, 1% nonessential
amino acids, 1% L-glutamine, and 1% sodium pyruvate and
antibiotics (all from Hyclone, Logan, UT, USA) at 37uCi na
humidified atmosphere containing 5% carbon dioxide.
Cell viability
MDA-MB-231 and D3H2LN cell viability was assessed using
the MTT-microculture tetrazolium assay [34]. The cells were then
incubated with different concentrations of BP7033Br or BP7033Br
ALK, for 72 h at 37uC in a 5% CO2-incubator. Optical density




5) were incubated with 500 mM BP7033Br or
200 mM BP7033Br ALK for 72 h. Adherent cells were harvested,
washed with cold PBS, then fixed with ice-cold 70% ethanol at
220uC for 1 h. Cells were then treated with RNAse A (200 mg/
mL) and stained with propidium iodide (50 mg/mL) at room
temperature for 30 min in the dark. After incubation, the red
fluorescent cells were analysed by flowcytometer (Becton Dick-
inson). DNA histograms were created using Cell Quest software
(Becton Dickinson) analysing 1610
4 events per sample. The
relative distribution of cells in the phases of the cell cycle was
calculated with ModFiLT software (Becton Dickinson).
Cell death detection
To reveal a phosphatidylserine translocation specific to early
apoptosis stage, the cells were stained with a FITC-labelled
annexin-V (Ann-V). The ultimate stage of apoptosis or the first
stage of necrosis was revealed by incorporation of PI, which enters
into the cells when cell membrane damage has occurred. Cells
(1610
5) were incubated with 500 mM BP7033Br or 200 mM
BP7033Br ALK for 72 h in serum-containing medium. No
organic vehicle was used since both BPs were soluble in water
or culture medium until 20 mM. In addition, cells were harvested
and apoptotic cells were determined using the Annexin V-FITC
Apoptosis Detection kit (Beckman coulter, Fullerton CA, USA).
Then, the cells were analysed by flow cytometry (Becton
Dickinson, Heilderberg, Germany).
Cell migration and invasion assay
Cell migration experiments were performed using migration
chambers containing 8 mm pore size (Becton Dickinson). Cells
(2,5610
5) with 125 mM of BPs were added to each insert (upper
chamber). 10% FCS-DMEM was used as chemoattractant. For
invasion assays, Boyden invasion chambers with 8 mm pore size
filters coated with Matrigel (Falcon, MA, USA) were used. After
24 h incubation, non-migrated cells in the upper chambers were
removed by wiping cells with a cotton swab. Then, cells on the
lower filter face were fixed, stained and counted. Results were
expressed as a percentage, relative to controls normalised to 100%.
Experiments were performed in triplicate.
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The serum-free conditioned media of MDA-MB-231 and
D3H2LN cells treated with both BPs for 24 h in 6-wells plates
were lyophilized. Lyophilized conditioned media were normal-
ized to the number of cells mixed with non-reducing LaemmLi
buffer and subjected into 10% SDS-polyacrylamide gels
containing 1 mg/mL gelatine in the presence or absence of
BP. The gel was washed 3 times at room temperature in a
solution containing 2.5% (v/v) Triton X-100 and incubated at
37uC for 24 h in 50 mM Tris/HCL, pH 7.5, 0.2 M NaCl,
5 mM CaCl2 and 0.05% Brij 35. The gel was stained for 60 min
with 0.25% (w/v) R-250 Coomassie blue in 45% (v/v)
methanol/10% (v/v) acetic acid and destained in 25% methanol
(v/v)/10% acetic acid (v/v).
Xenografts in nude mice
All in vivo experiments were carried out with local ethical
committee approval and accordingly to the UKCCCR guidelines.
Animals were kept in a temperature-controlled room on a 12: 12
light-dark schedule with food and water ad libitum. D3H2LN cells
(2610
6 cells) were inoculated subcutaneously (s.c) in 4-week-old
athymic nude mice (nu/nu, Janvier, France, n=21). Then, mice
were arbitrarily placed in control (n=7) and in each BPs treated
group (n=7). The administration of BP7033Br or BP7033Br ALK
(11 mg/kg) started 1 week after cell inoculation when tumors
reached 30 mm
3. The concentration of 11 mg/kg corresponds to
about 250 mM for BP7033 ALK and 500 mM for BP7033 if
considering the MW of both BPs and the mean mouse weight of
about 30 g. Control group received 0.1 mL of PBS 16.
Treatments or PBS solutions administration were intratumoral
twice a week for 4 weeks. Tumor volume was measured once a
week along to major axes using callipers. Tumor volume (mm
3)
was calculated as following: V=4/3pR1
2R2 where R1,R2
Tolerability of the dose used (11 mg/kg) was evaluated
according to the same protocol used for BPs injection on each
tumor and tumor-free healthy mice (n=5). Each animal was
weighted once a week during the treatment.
Immunohistochemical analysis
Tumour specimens were fixed in 4% paraformaldehyde and
embedded in to paraffin using standard procedure. Routinely,
5 mm-sections were stained in haematoxylin and eosin. For
immunohistochemical studies the sections were deparaffinized
and rehydrated. Endogenous peroxidase was inactivated with 3%
H2O2 and washed in TBS (Tris 0.05 M, NaCl 1.5 M, pH 7.6)
followed by pre-incubation in 10% normal goat serum for 1 h at
room temperature. Endothelial cells were specifically labelled with
GSL-1 isolectin B4 (Vector Laboratories, Burlingame, CA,
U.S.A.). The sections were incubated for 1 h with the 1:50 diluted
GSL-1 isolectin at room temperature. The sections were then
incubated with goat antibody against GSL-1 isolectin B4 (1:400
dilution, Vector Laboratories) for 30 min, washed with TBS and
incubated with biotinylated rabbit anti-goat immunoglobulins
(1:400 dilution; Dako,Glostrup, Denmark) for 20 min in a moist
chamber at room temperature. After three washes with TBS, the
samples were incubated with streptavidin-biotin peroxidase (LSAB
kit;Dako) for 10 min using diaminobenzidine tetrahydrochlorideas
the chromogen. Finally, the slides were washed in water and
counterstained with hematoxylin. Intratumor microvessel areas
were determined as described previously [20]. For each tumour,
10 randomly selected non serial sections were studied.
Intracardiac experimental metastasis model
Female nude mice (8–10 weeks) were anasthetized by
intraperitoneal injection of 120 mg/kg ketamine and 6 mg/kg
xylazine on the day of injection and by exposure to 1–3%
isoflurane on subsequent imaging days. On day 0, anaesthetized
animals were injected with D3H2LN (1610
5cells) in 100 ml sterile
PBS into the left ventricle of the heart by non surgical means.
Anesthetized mice were placed in the IVIS
TM Imaging System
(Xenogen) and imaged from both dorsal and ventral views
approximately 5 min after intraperitoneal injection of D-luciferin
(Caliper Life Science). A successful intracardiac injection was
indicated on day 0 by systemic bioluminescence distributed
throughout the animal. Only mice with satisfactory injection
continued the experiment and were treated by intraperitoneal
injection of PBS (control) or with both BPs (11 mg/kg). Assessment
of subsequent metastasis was monitored in vivo once a week by
imaging for up to 3 weeks.
Bioluminescent Imaging
Bioluminescence images were acquired with the IVIS imaging
system (Xenogen) at 5 min after intraperitoneal injection of D-
luciferin to anesthetized animals as described above. Acquisition
times of the beginning of the time course started at 5 min and were
reduced in accordance with signal strength to avoid saturation.
Analysis was performed using LivingImage software (Xenogen) by
measurement of photon flux (photon/s/cm
2) with a region of
interest (ROI) drawn around the bioluminescence signal.
Statistical analysis
Statistical significance was determined by the Student’s t-test.
P,0.05 was considered significant
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